Posts Tagged ‘One-Nucleus’
January 18, 2013 by IPAlchemist
It is now over a month since Genesis, the UK’s flagship life science and healthcare networking conference. I had always intended blogging about it – I was very excited to attend the whole event for the first time, because in previous years the most that I managed was to pop in for a little while, or attend the dinner. The problem is that, after the event was over, nothing really came into my mind that I wanted to say. So the blog piece got put off, until now, at the one-month stage, I feel I really need to write it, whatever.
Normally when I go to an event, I come away with something that I want to say, but on this occasion it didn’t really happen. It is not that I did not enjoy the event – I enjoyed it immensely. I met many interesting people for the first time, as well as running into various One Nucleus stalwarts that it was a pleasure to see again. There were of course many patent attorneys in attendance (although with some notable and noticeable absences), and it is rarely disappointing to meet a patent attorney. There were many interesting and stimulating discussions, as well as the formal presentations.
In particular I attended the afternoon session on Antibody-Based Therapeutics which yielded many fascinating brief stories (although one, which I feel I should not name, was basically “We have great idea but it is so early stage we can’t tell you what it is yet. It might not work – we don’t know yet, but if it does it will be amazing”).
In the morning I attended a case study on the deal between Astex, Cancer Research Technology and The Institute of Cancer Research relating, of course, to an anticancer compound. This revealed fascinating insights into how such complex deals come into existence and what drives the terms and the choice of partner.
I also attended the morning plenary session and the afternoon plenary debate. And perhaps that is the issue. Annual events such as Genesis prompt a certain amount of navel gazing. The industry as a whole, in its widest sense including service providers and academia as well as pharmaceutical and biotech companies of whatever type, considers “are we in good shape”? And now seems a particularly troubling time to ask this question, because, as the plenary debate made clear, one can equally argue for optimism pointing to all sorts of wonderful positive signs, as for pessimism pointing to all the harbingers of doom. And I wonder whether it might not be better if the answer was clearly negative, because then we could agree that there is a problem and do something about it: I feel maybe that the lack of consensus is itself the reason for the feeling of unease.
I will end on a harbinger of optimism, a fellow blogger that I have added to my blogroll, Lucy Robertshaw. Lucy was a model of optimism and enterprise, having moved from the UK to Sweden to set up her own consultancy company. She also cleverly worked out that if you get the right photo, you can do quite a short post! That was my APAA strategy, but foolishly I took no snaps at Genesis.